Title

A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.

Document Type

Journal Article

Publication Date

2-28-2017

Journal

Neuro-Oncology

Volume

19

Issue

8

Inclusive Pages

1135-1144

DOI

10.1093/neuonc/now282

Peer Reviewed

1